Tumor Mutational Burden in Metastatic Castration-Resistant Prostate Cancer and Response to Checkpoint Inhibition

被引：4
|
作者：
Zang, Peter D. [1 ]
Chawla, Neal S. [1 ]
Barragan-Carrillo, Regina [1 ]
Chehrazi-Raffle, Alex [1 ]
Tripathi, Abhishek [1 ]
Pal, Sumanta K. [1 ]
Dorff, Tanya B. [1 ]
机构：
[1] City Hope Comprehens Canc Ctr, Dept Med Oncol & Expt Therapeut, Duarte, CA USA
来源：
JAMA ONCOLOGY | 2024年 / 10卷 / 04期
关键词：
IPILIMUMAB;
D O I：
10.1001/jamaoncol.2023.6817
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
This single-center cohort study assesses the association of tumor mutational burden status in patients with metastatic castration-resistant prostate cancer and response to immune checkpoint inhibitor therapy.
引用
收藏
页码：531 / 532
页数：2
相关论文
共 50 条
  • [1] Comparative Effectiveness of Immune Checkpoint Inhibitors vs Chemotherapy by Tumor Mutational Burden in Metastatic Castration-Resistant Prostate Cancer
    Graf, Ryon P.
    Fisher, Virginia
    Weberpals, Janick
    Gjoerup, Ole
    Tierno, Marni B.
    Huang, Richard S. P.
    Sayegh, Nicolas
    Lin, Douglas, I
    Raskina, Kira
    Schrock, Alexa B.
    Severson, Eric
    Haberberger, James F.
    Ross, Jeffrey S.
    Creeden, James
    Levy, Mia A.
    Alexander, Brian M.
    Oxnard, Geoffrey R.
    Agarwal, Neeraj
    JAMA NETWORK OPEN, 2022, 5 (03)
  • [2] Metastatic castration-resistant prostate cancer and immune checkpoint inhibitors
    Pavlov, A. Yu.
    Dzidzaria, A. G.
    Gafanov, R. A.
    Samusevich, V. A.
    Mirzoev, E. E.
    Kortyshkova, A. O.
    Aivazov, M. T.
    Mirzoev, F. E.
    ONKOUROLOGIYA, 2024, 20 (01): : 153 - 163
  • [3] High Tumor Burden Predicts Poor Response to Enzalutamide in Metastatic Castration-Resistant Prostate Cancer Patients
    Hsieh, Yu-Ting
    Chiang, Bing-Juin
    Wu, Chia-Chang
    Liao, Chun-Hou
    Lin, Chia-Da
    Chen, Chung-Hsin
    CANCERS, 2021, 13 (16)
  • [4] BURDEN OF METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC) IN TURKEY
    Erdal, E.
    Malhan, S.
    Oksuz, E.
    Benekli, M.
    Cag, C.
    Dane, F.
    Kabasakal, L.
    Kucuk, O.
    Sozen, T. S.
    Sar, C.
    Kahveci, B.
    VALUE IN HEALTH, 2016, 19 (07) : A725 - A726
  • [5] Metastatic Castration-Resistant Prostate Cancer, Immune Checkpoint Inhibitors, and Beyond
    Lanka, Sree M.
    Zorko, Nicholas A.
    Antonarakis, Emmanuel S.
    Barata, Pedro C.
    CURRENT ONCOLOGY, 2023, 30 (04) : 4246 - 4256
  • [6] Metastatic castration-resistant prostate cancer
    Henriques, Vanessa
    Wenzel, Mike
    Demes, Melanie-Christin
    Koellermann, Jens
    PATHOLOGE, 2021, 42 (04): : 431 - 438
  • [7] Circulating Tumor Cells in Metastatic Castration-Resistant Prostate Cancer
    Rini, Brian I.
    CURRENT ONCOLOGY REPORTS, 2009, 11 (03) : 163 - 164
  • [8] Circulating tumor cells in metastatic castration-resistant prostate cancer
    Brian I. Rini
    Current Oncology Reports, 2009, 11 : 163 - 164
  • [9] Elevated driver mutational burden or number of perturbed pathways and poor response to abiraterone or enzalutamide in metastatic castration-resistant prostate cancer
    De Laere, B.
    Crippa, A.
    Ghysel, C.
    Ost, P.
    Rajan, P.
    Eklund, M.
    Dirix, L.
    Gronberg, H.
    Lindberg, J.
    ANNALS OF ONCOLOGY, 2019, 30
  • [10] Comparative Effectiveness of Immune Checkpoint Inhibitors vs Chemotherapy by Tumor Mutational Burden in Metastatic Castration-Resistant Prostate Cancer (vol 5, e225394, 2022)
    Graf, R. P.
    Fisher, V
    Weberpals, J.
    JAMA NETWORK OPEN, 2022, 5 (05)
12345